Neuralstem will sponsor stem cell research at the China Medical University & Hospital of Taiwan. The work will help prepare for a human clinical trial using Neuralstem’s human spinal cord neural stem cells to treat patients who have suffered a stroke. The patient population will be limited to those whose post-stroke symptoms (complete or partial paralysis) have stopped improving more than six months after an ischemic stroke. More details...

Stock Symbol: (NYSE Amex: CUR)